SpringWorks Therapeutics (SWTX) Corporate Presentation summary

Strategic overview and financial position

• Multi-product targeted oncology company with OGSIVEO and GOMEKLI as lead assets, both first and only FDA-approved therapies in their indications.

• Geographic expansion and diversified pipeline broaden growth opportunities, with profitability expected in 1H 2026.

• Strong financials: $461.9M in cash and no debt as of December 2024, fully funded through expected profitability.

• Durable intellectual property protection for lead programs, with patent expiries into the 2040s and orphan drug exclusivity.

• Robust commercial foundation with $172M in 2024 net product revenue and growing patient demand.

OGSIVEO (nirogacestat) for desmoid tumors

• First and only FDA-approved therapy, rapidly established as systemic standard of care with strong physician preference.

• $172M net revenue in first full year, with sustained quarterly growth and broad adoption across treatment stages.

• Demonstrated significant clinical benefits: improved progression-free survival, pain reduction, and quality of life.

• Long-term data show increased objective response rate and tumor reduction with extended treatment.

• International expansion underway, with EU approval and launch in Germany anticipated mid-2025.

GOMEKLI (mirdametinib) for NF1-PN

• First and only FDA-approved treatment for both adult and pediatric patients with NF1-associated plexiform neurofibromas.

• Differentiated profile: robust and durable responses, manageable safety, and convenient oral formulation.

• Addresses a large unmet need, with ~30,000 adult and ~10,000 pediatric patients in the U.S.

• Launch underway in the U.S.; international expansion planned with EU approval expected in 2025.

• Strong physician support and high likelihood of rapid adoption as standard of care.